主动脉瓣狭窄患者瓣膜置换术后心肌逆重构
本研究纳入181例症状性重度主动脉瓣狭窄患者,在瓣膜置换术前及术后1年用心脏磁共振测量细胞外容积分数等指标。术后1年116例无起搏器幸存者平均跨瓣压差改善,左室质量指数下降19%,弥漫性纤维化(基质容积)消退16%,细胞容积消退22%,而局灶性纤维化无变化,伴舒张功能及临床症状改善。
要点
- 主动脉瓣置换术后1年左室质量指数消退19%,弥漫性纤维化消退16%,细胞肥大消退22%。
- 局灶性纤维化(晚期钆增强)术后未消退,而弥漫性纤维化具有可逆性。
- 纤维化消退伴随舒张功能、NT-proBNP、6分钟步行试验及NYHA心功能分级改善。
核心结论
- 主动脉瓣置换术后局灶性纤维化不消退,但弥漫性纤维化和心肌细胞肥大可消退。
- 弥漫性纤维化具有可塑性,可通过心脏磁共振测量,可能是潜在治疗靶点。
研究设计与样本
- 前瞻性研究纳入181例症状性重度主动脉瓣狭窄患者(瓣口面积指数0.4±0.1 cm2/m2),术前及术后1年评估。
- 评估手段包括超声心动图、心脏磁共振(测量细胞外容积分数并推导基质容积和细胞容积)、生物标志物及6分钟步行试验。
- 术后1年随访完成116例无起搏器幸存者(年龄70±10岁,54%男性)。
主要发现
- 术后1年平均跨瓣压差从48±16 mm Hg改善至12±6 mm Hg(p<0.001)。
- 左室质量指数消退19%(88±26 g/m2降至71±19 g/m2;p<0.001)。
- 细胞外容积分数增加(28.2±2.9%升至29.9±4.0%;p<0.001),源于基质容积消退16%(25±9 ml/m2降至21±7 ml/m2;p<0.001)和细胞容积消退22%(64±18 ml/m2降至50±13 ml/m2;p<0.001)。
- 局灶性纤维化(晚期钆增强)术后无变化。
- 舒张功能、N末端B型利钠肽前体、6分钟步行试验结果及NYHA心功能分级均改善。
临床怎么用
- 主动脉瓣置换术后应关注心肌逆重构,包括弥漫性纤维化和细胞肥大的消退。
- 心脏磁共振测量的细胞外容积分数可用于评估弥漫性纤维化及其逆转。
- 局灶性纤维化术后不消退,提示需早期干预以避免不可逆心肌损害。
局限性
- 术后1年随访仅116例无起搏器幸存者,存在选择偏倚可能。
- 单中心研究,样本量有限。
- 未报告局灶性纤维化与弥漫性纤维化逆转差异的机制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Left ventricular (LV) hypertrophy, a key process in human cardiac disease, results from cellular (hypertrophy) and extracellular matrix expansion (interstitial fibrosis). OBJECTIVES: This study sought to investigate whether human myocardial interstitial fibrosis in aortic stenosis (AS) is plastic and can regress. METHODS: Patients with symptomatic, severe AS (n = 181; aortic valve area index 0.4 ± 0.1 cm2/m2) were assessed pre-aortic valve replacement (AVR) by echocardiography (AS severity, diastology), cardiovascular magnetic resonance (CMR) (for volumes, function, and focal or diffuse fibrosis), biomarkers (N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T), and the 6-min walk test. CMR was used to measure the extracellular volume fraction (ECV), thereby deriving matrix volume (LV mass × ECV) and cell volume (LV mass × [1 - ECV]). Biopsy excluded occult bystander disease. Assessment was repeated at 1 year post-AVR. RESULTS: At 1 year post-AVR in 116 pacemaker-free survivors (age 70 ± 10 years; 54% male), mean valve gradient had improved (48 ± 16 mm Hg to 12 ± 6 mm Hg; p < 0.001), and indexed LV mass had regressed by 19% (88 ± 26 g/m2 to 71 ± 19 g/m2; p < 0.001). Focal fibrosis by CMR late gadolinium enhancement did not change, but ECV increased (28.2 ± 2.9% to 29.9 ± 4.0%; p < 0.001): this was the result of a 16% reduction in matrix volume (25 ± 9 ml/m2 to 21 ± 7 ml/m2; p < 0.001) but a proportionally greater 22% reduction in cell volume (64 ± 18 ml/m2 to 50 ± 13 ml/m2; p < 0.001). These changes were accompanied by improvement in diastolic function, N-terminal pro-B-type natriuretic peptide, 6-min walk test results, and New York Heart Association functional class. CONCLUSIONS: Post-AVR, focal fibrosis does not resolve, but diffuse fibrosis and myocardial cellular hypertrophy regress. Regression is accompanied by structural and functional improvements suggesting that human diffuse fibrosis is plastic, measurable by CMR and a potential therapeutic target. (Regression of Myocardial Fibrosis After Aortic Valve Replacement; NCT02174471).
引用
- Treibel TA, Kozor R, Schofield R, et al. Reverse Myocardial Remodeling Following Valve Replacement in Patients With Aortic Stenosis. J Am Coll Cardiol. 2018. PMID: 29471937. doi:10.1016/j.jacc.2017.12.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。